Osoba, D.

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 16,005

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 929

Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients

Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., Martinelli, F., Reeve, B. B., Gotay, C., Greimel, E., et al. (2011) · Annals of Oncology

Cancer survivorship and careHealth Systems, Economic Evaluations, Quality of Life

Cited by 161

Methods for explaining the clinical significance of health status measures

Guyatt, G., Osoba, D., Wu, A., Wyrwich, K., & Norman, G. (2002) · Clinical Therapeutics

Health Systems, Economic Evaluations, Quality of LifePsychometric Methodologies and Testing

Cited by 10